Nextech Invest — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
BiotechLondon
James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)
Co-investorsForesite CapitalMC Healthcare VenturesVivo Capital
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)
BoardJohn Park(Executive Officer)John Clarke(Executive Officer, Director)in
Board seatBenjamin Cravatt· per SEC Form D
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsCardinal PartnersSoftBank Vision FundVersant Ventures
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersOrbiMedVida VenturesDigitalis VenturesNVIDIA
BiotechCambridge, US
William C. Shakespeare(Director)
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)Carl Gordon(Director)in
Co-investorsForesite CapitalLongitude CapitalOrbiMed
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.